Clinical trial
Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00023647 · Mannkind Corporation, Industry · Completed
Key facts
| NCT number | NCT00023647 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IV Melanoma |
| Official title | A Phase I Dose-Ranging Safety Study Using Intranodal Delivery of a Plasmid DNA (Synchrotope TA2M) in Adult Stage IV Melanoma Patients |
| Lead sponsor | Mannkind Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | Synchrotope TA2M |
| Enrollment | 26 |
| Start date | Jul 1, 2000 |
| Primary completion | Apr 1, 2002 |
| Completion | Nov 1, 2002 |
| First posted | Feb 16, 2004 |
| Last update posted | Jul 10, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: